April twenty _ seventhDiamondrouletteShengxiang Biology, an A-share listed company, released its annual performance report for 2023. Of which, net profit 3Diamondroulette.64 billion yuan, down 81.22 percent from the same period last year.

According to the comprehensive operation and follow-up analysis of more than 1200 financial indicators of its financial data in the current period and the past five years, according to the financial diagnosis model of flush (300033), the overall financial situation of Shengxiang biology in the past five years is OK. Specifically, solvency, cash flow, asset quality and profitability are good.

The net profit was 364 million yuan, down 81.22% from the same period last year.

In terms of revenue and profit, the company's total operating income during the reporting period was 1.007 billion yuan, down 84.39% from the same period last year, and the net profit was 364 million yuan, down 81.22% from the same period last year.

In terms of assets, during the company's reporting period, the total assets at the end of the period were 8.454 billion yuan and accounts receivable were 690 million yuan; in terms of cash flow, the net cash flow generated by business activities was 43.5396 million yuan, and the cash received by selling goods and providing services was 1.633 billion yuan.

At the same time, the company issued a forecast for the first quarter of 2023, which is expected to be from 2024-01-01 to 2024-03-31 performance: net profit of about 81.4891 million yuan; growth rate of about 35.79%; performance of the same period last year: net profit of 60.0129 million yuan.

With regard to the reasons for the changes in performance in the first quarter of 2024, the company said: under the background of the country's efforts to promote the high-quality development of the life and health industry, the company has gradually entered a period of development in multi-track and multi-fields by virtue of early forward-looking strategic planning and investment layout. Endogenous drive and epitaxial growth go hand in hand, showing strong growth potential. At the same time, the company actively captures and makes use of market opportunities to promote the breadth and depth of product coverage, provide more solutions for hospitals, disease control, community, Internet and other scenarios, further improve product performance and optimize customer experience, effectively achieve coordinated business growth, improve the influence of the company's brand, and lay a solid foundation for sustainable development in the future.

There are four financial highlights.

According to the relevant financial information published by Shengxiang Biology, there are four financial bright spots in the company, as follows:

The index type reviews that the liquidity ratio is 8.48 and the short-term solvency is excellent. Cash flow free cash flow accounts for an average of 69.68% of income, ranking first in the industry. The revenue of the growth period increased by 100.31% compared with the same period last year, and the revenue growth performance was excellent. The deduction of non-net profit in the growth period increased by 1962.06% compared with the same period last year, and the profit growth performance was excellent.

There are three financial risks

According to the relevant financial information published by Shengxiang Biology, there are three financial risks in the company, as follows:

The average turnover rate of accounts receivable is 1.41 (times / year). There is a great pressure on the company to collect accounts. The average turnover rate of inventory is 0.81 (times / year), and the ability to realize inventory is poor. The average turnover rate of total operating assets is 0.14 (times / year), and the operating capacity of the company is very low.

Overall, the overall financial situation of Shengxiang Biology is OK, with a current total score of 2.11, ranking low among 126 companies in the medical device industry. Specifically, solvency, cash flow, asset quality and profitability are good.

The scores of the indicators are as follows:

Index type previous period score ranking evaluation growth ability 1.900.91104 weaker operating ability 3.270.16123 poor solvency 4.073.3343 stronger cash flow 4.403.2944 good asset quality 3.513.1747 higher profitability 2.943.0650 good total score 3.112.1181

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >

(: congratulations